EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the third conference on European Reference Networks (ERNs) this month in Vilnius, Lithuania, EuroBloodNet was officially announced as one of the recently approved ERNs.
PHOENIX – Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by myeloma. The findings are published in Nature Medicine. Myeloma is a blood cancer that affects plasma cells – white blood cells that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body,…
